Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PDT, NAT

CUNY SPH Launches CONVINCE USA Initiative to Understand and Address Public Concerns about COVID-19 Vaccines


NEW YORK, Dec. 2, 2020 /PRNewswire/ -- The City University of New York Graduate School of Public Health and Health Policy (CUNY SPH) today launched CONVINCE USAsm, part of a global project to increase understanding of factors that influence people's willingness to accept new COVID-19 vaccines, and to promote inclusive public dialogue to reduce vaccine hesitancy.

As part of the global, multi-sector CONVINCEsm (COVID-19 New Vaccine Information Communication and Engagement) initiative with the Vaccine Confidence Project (VCP) at the London School of Hygiene & Tropical Medicine (LSHTM) and Wilton Park, CONVINCE USA will work at the national, state and local level, across the public, private and NGO sectors, and will include both independent and collaborative programs to create support for COVID-19 immunization and the science behind it.

"The need for our initiative is clear, given recent survey research that has identified high levels of potential refusal of a COVID-19 vaccine both here in New York City and nationally," said Dr. Ayman El-Mohandes, Dean of CUNY SPH. "CONVINCE USA will be directed at CUNY SPH by its co-founder, Professor Scott Ratzan."

Dr. Ratzan, Distinguished Lecturer at CUNY SPH and Editor of the Journal of Health Communication: International Perspectives, explained, "We have already been fortunate to obtain support from The Commonwealth Fund, CDC Foundation, and the Community Health Acceleration Partnership to undertake new research at CUNY SPH that will lead to the development of guidance to help public health workers and the private sector implement successful COVID-19 immunization campaigns, as approved vaccines become available in the coming months." 

The CONVINCE USA project grew out of a series of global dialogues over the course of the pandemic with CUNY SPH, the VCP, and Wilton Park, an agency of the UK Foreign, Commonwealth, and Development Office.

"We look forward to using the insights on vaccine hesitancy that VCP has gathered globally over the last decade to help CONVINCE USA develop effective new communication and engagement strategies," said Professor Heidi Larson, Director of the VCP.

The Wilton Park dialogues that provided the initial impetus for the CONVINCE initiative will continue to yield fresh insights and bring in new voices and ideas going forward. "Our goal is to find collaborative solutions that will help us all to break free of the pandemic and restore people's lives and livelihoods," stated Nancy Lee, Programme Director for Global Health and Health Policy at Wilton Park.

Convince USA  projects will be supported by a high-level advisory group that includes Dr. Jonathan Fielding, Distinguished Professor-in-Residence at UCLA Fielding School of Public Health; Dr. Margaret Hamburg, Board Chair of the American Association for the Advancement of Science; Dr. David Nabarro, the WHO Director's Special Envoy on COVID-19; Lawrence Gostin, Director of the WHO Collaborating Center on National & Global Health Law; and Bill Novelli, Distinguished Professor at Georgetown University McDonough School of Business; and Dr. Helene Gayle, President & CEO, Chicago Community Trust.

Learn more about CONVINCE at https://sph.cuny.edu/research/convince/.

Contact:
Ariana Costakes
646-549-4892
[email protected]

SOURCE CUNY SPH


These press releases may also interest you

at 12:07
The Women in Insurance Cancer Crusade (WICC) took another step closer to its goal of raising $25 million by 2025 at their annual Relay for Life fundraising event, held on June 6th . Nearly 300 people came together for an evening of camaraderie for...

at 12:00
"I wanted to create a simple and attractive way to secure your glasses to your shirt, jacket or other article of clothing," said an inventor, from Port St. Lucie, Fla., "so I invented the EYEGLASS PIN HOLDER. My design enables you to keep your...

at 11:56
Northwest Biotherapeutics ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on June 29, 2024. ...

at 11:32
The American Parkinson Disease Association (APDA) is celebrating the President's signing of the National Plan to End Parkinson's Act yesterday, marking the enactment of the first-ever federal legislation dedicated to curing and preventing Parkinson's...

at 11:30
NeuroCytonix, Inc., today announced that on May 27, 2024, its subsidiary NeuroCytonix Mexico received a regulatory approval letter from the ethical, scientific, and safety committees of Hospital La Mision in Monterrey, Mexico, to launch a clinical...

at 11:00
States with high rates of COVID-19 vaccination saw more pediatric asthma patients get a break from their symptoms, according to new research published today in JAMA Network Open by leaders from Nemours Children's Health and Endeavor Health....



News published on and distributed by: